In this multicohort study, we investigated whether tau-PET, a marker of aggregated tau pathology, or plasma p-tau217, a marker of soluble hyperphosphorylated tau, is more strongly associated with future cognitive decline among 1,474 CU individuals and whether they would provide complementary information in screening approaches for clinical trials. This evidence concerns the gene MAPT and Mental deterioration.